Skip to content
BiologicalX

Comparison

Magnesium Glycinate vs Tirzepatide

Side-by-side of Magnesium Glycinate and Tirzepatide. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.

Effects at a glance

Magnesium Glycinate

  • Shortens sleep onset latency in older adults and in deficient populations supplementing 200 to 400 mg elemental Mg
  • Improves subjective sleep quality scores (PSQI, ISI) modestly versus placebo over 4 to 8 weeks
  • Reduces nocturnal leg cramps and exercise-induced muscle cramping in some controlled trials
  • Lowers self-reported anxiety in mild-to-moderate cases, with smaller effect than first-line pharmacotherapy
  • Glycinate form delivers fewer GI side effects than oxide or citrate at equivalent elemental doses
  • Insufficient as a stand-alone hypertension treatment; small adjunctive blood-pressure reductions only

Tirzepatide

  • Dual GIP plus GLP-1 receptor agonist with a ~5-day half-life supporting once-weekly subcutaneous dosing
  • SURMOUNT-1 reported ~22.5% mean body-weight loss at 15 mg over 72 weeks versus 2.4% on placebo
  • Lowers HbA1c by ~1.9 to 2.6 percentage points in type 2 diabetes across SURPASS trials
  • Outperformed semaglutide 1.0 mg head-to-head on weight loss and HbA1c in SURPASS-2
  • GI effects (nausea, diarrhea, vomiting) drive most discontinuations and ease with slow titration
  • Lean-mass loss observed in body-composition substudies; resistance training and protein intake mitigate this

Side-by-side

Attribute Magnesium Glycinate Tirzepatide
Category supplement pharmaceutical
Also known as magnesium bisglycinate Mounjaro, Zepbound, LY3298176
Half-life (hr) 5 120
Typical dose (mg) 300 10
Dosing frequency daily (often evening) weekly
Routes oral subcutaneous
Onset (hr) 1 24
Peak (hr) - 72
Molecular weight - 4813.45
Molecular formula - C225H348N48O68
Mechanism Magnesium acts as a cofactor for 300+ enzymes and as a voltage-dependent antagonist at NMDA receptors; glycine serves as an inhibitory neurotransmitter and co-agonist at glycine receptors. Synthetic 39-amino-acid peptide that activates both GIP and GLP-1 receptors. Potentiates glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and acts on hypothalamic and brainstem satiety circuits.
Legal status Dietary supplement Prescription only; FDA-approved 2022 (T2DM, Mounjaro) and 2023 (chronic weight management, Zepbound)
WADA status allowed allowed
DEA / Rx OTC supplement Rx only (not a controlled substance)
Pregnancy Generally considered acceptable at RDA doses; consult clinician Not recommended; discontinue 2 months before planned pregnancy
CAS 14783-68-7 2023788-19-2
PubChem CID 84645 156588324
Wikidata - Q105099794

Safety profile

Magnesium Glycinate

Common side effects

  • mild GI upset at high doses
  • loose stools (dose-dependent, less than with oxide/citrate forms)

Contraindications

  • severe renal impairment
  • myasthenia gravis
  • heart block

Interactions

  • tetracycline and fluoroquinolone antibiotics: magnesium chelates antibiotic, reducing absorption; separate by 2+ hours(moderate)
  • bisphosphonates: reduced absorption of bisphosphonate(moderate)
  • potassium-sparing diuretics: possible hypermagnesemia in renal impairment(moderate)

Tirzepatide

Common side effects

  • nausea
  • diarrhea
  • vomiting
  • constipation
  • decreased appetite
  • injection-site reactions
  • fatigue
  • abdominal pain

Contraindications

  • personal or family history of medullary thyroid carcinoma
  • multiple endocrine neoplasia type 2
  • pregnancy
  • history of pancreatitis (use caution)
  • severe gastroparesis

Interactions

  • insulin: additive hypoglycemia risk; insulin dose typically reduced(major)
  • sulfonylureas (glipizide, glyburide): hypoglycemia risk, sulfonylurea dose often reduced(major)
  • oral medications (general): delayed gastric emptying can alter absorption kinetics(moderate)
  • oral contraceptives: reduced exposure after first dose; backup contraception recommended for 4 weeks after initiation and each dose escalation(moderate)
  • warfarin: monitor INR due to altered absorption(moderate)

Which Should You Take?

Magnesium Glycinate comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-A outcome catalogued. Tirzepatide is the right call when one of the conditionals below applies.

Edge case: If you want to avoid prescription-only, Magnesium Glycinate is the more accessible choice.

Default choice: Magnesium Glycinate. Lower friction to source, a Tier-A evidence outcome catalogued, and broader goal coverage. Reach for Tirzepatide only if your priority sits squarely in the goals it owns above.

This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.

Common questions

What is the difference between Magnesium Glycinate and Tirzepatide?

Magnesium Glycinate and Tirzepatide differ in category (supplement vs pharmaceutical), mechanism, and typical dosing. See the side-by-side table for full details.

Which has a longer half-life, Magnesium Glycinate or Tirzepatide?

Magnesium Glycinate half-life is 5 hours; Tirzepatide half-life is 120 hours.

Can you stack Magnesium Glycinate with Tirzepatide?

Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.

Go deeper